Developer docs
API playgroundTry for free, no card

Search company profiles

Animascure

Full company profile

uuid000ezbm

Namestring
Animascure
Legal namestring
AnimusCure Inc. (애니머스큐어 주식회사)
Websiteurl
animuscure.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

AniMusCure is a South Korea-based, clinical-stage biotechnology company founded in 2020 by two academic co-founders (Professor Bae Gyu-Un of Sookmyung Women's University and Professor Jongsoon Kang of Sungkyunkwan University) that develops first-in-class therapeutics targeting muscle diseases. The company's core scientific thesis is that its proprietary target-gene approach can simultaneously increase muscle mass, enhance muscle strength, and improve muscle function — a triple-action profile that the company states major pharmaceutical players have been unable to achieve. Its lead candidate AMC6156 is in a Phase 2 trial in Korea for age-related sarcopenia (results expected June 2026) and has received FDA Orphan Drug Designation for ALS; AMC8012 has FDA Orphan Drug Designation for Duchenne Muscular Dystrophy; additional pipeline assets address metabolic sarcopenia (AMC9005), obesity combination therapy (AMC8011, evaluated in GLP-1 combinations), and cancer cachexia (AMC6133).

Underlying R&D is anchored by two proprietary platforms: the AI-powered MyoCheck drug discovery system, which integrates a compound library with big-data analytics and in vitro/in vivo validation to identify lead compounds in 3-6 months, and an hiPSC-based organoid platform that includes what the company describes as the world's first heart organoid recapitulating cardiac tube formation, looping, and twisting, plus a NeuroMuscular organoid exhibiting synchronous contractile activity for aging, toxicity, and disease modeling with deep-learning image analysis. Multiple patent applications have been filed in Korea and via PCT, and joint patent applications exist with Dongwha Pharmaceutical.

The business model is B2B pharmaceutical licensing and co-development: the company partners with Korean pharmaceutical firms (Dongwha, REYON, Il-Yang, Samik Pharma) who contribute synthesis, formulation, and commercialization capabilities while AniMusCure contributes mechanism research and AI-led lead optimization, with future revenue expected from licensing royalties and overseas technology export. Clinical operations are outsourced via a CRO agreement with Novotech, and Phase 2 trials are conducted at Seoul National University Hospital and three other Korean sites. A complementary consumer revenue stream was added in December 2024 with the launch of M-Qure Plus, a liquid magnesium health functional food, representing a non-Rx, channel-based sales motion alongside the prescription pipeline.

Short descriptiontext

AniMusCure is a South Korean clinical-stage biotech developing first-in-class therapeutics for sarcopenia, DMD, ALS, and other muscle diseases using proprietary AI-powered MyoCheck and hiPSC organoid platforms, monetizing through pharma licensing and co-development with Dongwha, REYON, and Il-Yang.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersCheongcheon, South Korea
HQ citystring
Cheongcheon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
muscle disease therapeutics, sarcopenia drug development, AI drug discovery platform, hiPSC organoid technology, orphan drug designation
Industry5 codes
PRIMARYHLAKAIAD
Neuromuscular Medicine (ALS, Myasthenia, Neuropathy)
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHSADAFAC
Weight Gain & Muscle-Building Nutrition
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Muscle Disease Therapeutics R&D
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Licensing
TypeLicensing Royalties
Description

Pre-revenue biotech company focused on developing novel therapeutics for muscle diseases including sarcopenia, DMD, ALS, and cardiovascular conditions. Revenue expected through licensing deals with global pharmaceutical companies, co-development agreements, and eventual product commercialization.

animuscure.com
2Health Functional Food Sales
TypeHardware Sales
Description

Launched M-Qure Plus liquid magnesium product in December 2024 for muscle health, representing a consumer health product revenue stream.

animuscure.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1M-Qure Plus
Description

Health functional food - liquid magnesium supplement for muscle health launched in December 2024

animuscure.com
Core offering1 text field

Animascure is a clinical-stage biotechnology company developing first-in-class small-molecule drug candidates that simultaneously increase muscle mass, enhance muscle strength, and improve muscle function for sarcopenia, DMD, ALS, cancer cachexia, metabolic syndrome, and cardiovascular indications. Its drug discovery is powered by the proprietary AI-driven MyoCheck® platform and hiPSC-based NeuroMuscular and Heart Organoid modeling platforms, with future revenue expected from out-licensing and co-development deals with global pharmaceutical partners and a current consumer revenue stream from the M-Qure Plus liquid magnesium health supplement.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Candidate compound identification within 3-6 months using MyoCheck platform
+1 more record
Product overview1 text field

AnimusCure is a muscle-focused R&D biotechnology company developing a portfolio of drug candidates for muscle-related diseases. The core product pipeline includes AMC6156 for sarcopenia and ALS, AMC8012 for DMD, AMC9005 for metabolic syndrome, AMC8011 for obesity combination therapy, and AMC6133 for cancer cachexia. The company operates two technology platforms: the AI-powered MyoCheck® Platform for drug discovery enabling rapid candidate identification within 3-6 months, and the Organoid Platform using hiPSC-based neuromuscular and heart organoids for disease modeling and drug evaluation. Additionally, the company launched M-Qure Plus, a liquid magnesium health supplement for muscle health in January 2025.

Product and service6 records
1AMC6156
CategoryDrug candidate
Description

Lead small-molecule drug candidate targeting age-related sarcopenia with a first-in-class triple-action mechanism that simultaneously increases muscle mass, enhances muscle strength, and improves muscle function. Currently in Phase 2 clinical trials in Korea for sarcopenia and has received FDA Orphan Drug Designation for ALS.

2AMC8012
CategoryDrug candidate
Description

Drug candidate for Duchenne Muscular Dystrophy (DMD), a rare congenital muscle disease, with FDA Orphan Drug Designation. Targets progressive muscle degeneration in pediatric and rare-disease populations.

3AMC9005
CategoryDrug candidate
Description

Drug candidate for metabolic syndrome including obesity treatment, with FDA Orphan Drug Designation approved. Developed through the proprietary core target gene-based therapeutic approach.

4AMC8011
CategoryDrug candidate
Description

Obesity combination therapy drug candidate designed to address muscle-loss side effects associated with GLP-1 weight-loss drugs; third-party efficacy study completed in combination with GLP-1.

5AMC6133
CategoryDrug candidate
Description

Drug candidate targeting cancer cachexia, the muscle-wasting syndrome associated with malignancy and oncology treatments.

6M-Qure Plus
CategoryHealth functional food
Description

Liquid magnesium dietary supplement marketed as a health functional food for muscle health, providing a consumer-facing revenue stream alongside the pharmaceutical pipeline.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1REYON Pharmaceutical (이연제약)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-07
Description

Joint research agreement signed for age-related sarcopenia treatment development. Both companies utilizing their strengths to conduct joint R&D with goals of overseas technology export and domestic approval acquisition.

animuscure.com
2Il-Yang Pharmaceutical
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-07
Description

Memorandum of understanding signed for joint R&D on age-related sarcopenia therapeutics. Partnership aims for overseas technology export and domestic regulatory approval.

animuscure.com
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-07-03
Description

CRO agreement for Phase 2a clinical trial of AMC6156 sarcopenia treatment. Novotech serves as clinical research organization for trial conduct and management.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-31
Description

Joint research agreement for sarcopenia treatment development. Dongwha Pharmaceutical synthesizes and derives sarcopenia treatment candidates using low-molecule compound-based new drug development capabilities. AniMusCure conducts efficacy evaluation and mechanism research. Joint patent applications filed with Dongwha receiving commercialization rights.

5Samik Pharma (삼익제약)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-06-13
Description

Academic-industry collaboration with Sookmyung Pharmacy School and AniMusCure for muscle disease therapeutic development. Samik Pharma invests research funding and handles drug characterization, formulation optimization, and IND filing. AniMusCure conducts mechanism of action research and AI-based lead optimization.

animuscure.com
6Sookmyung Women's University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partner hosting AniMusCure's headquarters and 2nd Research Institute at the university. CEO Bae Gyu-Un serves as professor at the College of Pharmacy and directs the Muscle Physiome Research Center (MRC).

animuscure.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partner hosting AniMusCure's 1st Research Institute at the School of Medicine. CTO Jongsoon Kang serves as professor at the School of Medicine and leads ARPA-H project for sarcopenia therapeutics.

Strategic tierMinorTypeOthers
Description

Listed as partner in company materials, nature of partnership not detailed in available sources.

Strategic tierMinorTypeOthers
Description

Listed as partner in company materials, nature of partnership not detailed in available sources.

10Asymchem
Strategic tierMinorTypeOthers
Description

Listed as partner in company materials, nature of partnership not detailed in available sources.

animuscure.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage leader in Duchenne Muscular Dystrophy with multiple approved RNA-based therapies (Elevidys, Exondys 51, Vyondys 53). Directly comparable for the DMD program (AMC8012) given same indication and rare-disease commercial dynamics.

TypeBroad incumbent
Description

Large-cap biotech with muscle-related programs (e.g., garetosmab for fibrodysplasia ossificans progressiva) and broad rare-disease portfolio. Comparable as a potential global partner/acquirer with the capital to in-license sarcopenia assets.

TypeEmerging player
Description

Clinical-stage gene therapy company with focus on genetic cardiomyopathies and rare diseases. Comparable as a platform-oriented biotech tackling muscle/cardiovascular rare diseases at similar stage.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics targeting TGF-beta superfamily for blood disorders and muscle/bone diseases. Comparable given shared muscle-biology focus and similar clinical-stage profile.

5Avidity Biosciences
TypeDirect peer
Description

Clinical-stage biotech developing Antibody Oligonucleotide Conjugates for rare muscle diseases including DMD, FSHD, and DM1. Directly comparable given shared DMD focus and rare muscle-disease strategy.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics that target the molecular mechanisms of aging, with a lead program for sarcopenia. Most directly comparable to AnimusCure given shared sarcopenia focus, AI-driven discovery, and similar stage of development.

TypeBroad incumbent
Description

Large biotech with established ALS franchise (Spinraza, Relyvrio withdrawal) and active neuromuscular pipeline. Comparable as a likely acquirer/licensor for AnimusCure's ALS program and as a broad neuromuscular incumbent.

TypeDirect peer
Description

Late-stage biotech specializing in muscle biology and cardiac contractility, with approved cardiac myosin inhibitor and pipeline in HCM and muscle function. Directly comparable for muscle-targeted therapeutics development and clinical execution.

TypeDirect peer
Description

Clinical-stage biotech developing monoclonal antibodies targeting latent myostatin and TGF-beta superfamily for muscle disorders including SMA and DMD. Closely comparable given muscle-disease focus and similar therapeutic modality ambition.

TypeBroad incumbent
Description

Commercial rare-disease biotech with approved ARIKAYCE and pipeline in pulmonary and rare diseases. Comparable given rare-disease commercialization playbook and orphan-drug expertise applicable to AnimusCure's DMD/ALS programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Animascure

Muscle Disease Therapeutics R&Danimuscure.com

AniMusCure is a South Korean clinical-stage biotech developing first-in-class therapeutics for sarcopenia, DMD, ALS, and other muscle diseases using proprietary AI-powered MyoCheck and hiPSC organoid platforms, monetizing through pharma licensing and co-development with Dongwha, REYON, and Il-Yang.

What Animascure does

AniMusCure is a South Korea-based, clinical-stage biotechnology company founded in 2020 by two academic co-founders (Professor Bae Gyu-Un of Sookmyung Women's University and Professor Jongsoon Kang of Sungkyunkwan University) that develops first-in-class therapeutics targeting muscle diseases. The company's core scientific thesis is that its proprietary target-gene approach can simultaneously increase muscle mass, enhance muscle strength, and improve muscle function — a triple-action profile that the company states major pharmaceutical players have been unable to achieve. Its lead candidate AMC6156 is in a Phase 2 trial in Korea for age-related sarcopenia (results expected June 2026) and has received FDA Orphan Drug Designation for ALS; AMC8012 has FDA Orphan Drug Designation for Duchenne Muscular Dystrophy; additional pipeline assets address metabolic sarcopenia (AMC9005), obesity combination therapy (AMC8011, evaluated in GLP-1 combinations), and cancer cachexia (AMC6133).

Underlying R&D is anchored by two proprietary platforms: the AI-powered MyoCheck drug discovery system, which integrates a compound library with big-data analytics and in vitro/in vivo validation to identify lead compounds in 3-6 months, and an hiPSC-based organoid platform that includes what the company describes as the world's first heart organoid recapitulating cardiac tube formation, looping, and twisting, plus a NeuroMuscular organoid exhibiting synchronous contractile activity for aging, toxicity, and disease modeling with deep-learning image analysis. Multiple patent applications have been filed in Korea and via PCT, and joint patent applications exist with Dongwha Pharmaceutical.

The business model is B2B pharmaceutical licensing and co-development: the company partners with Korean pharmaceutical firms (Dongwha, REYON, Il-Yang, Samik Pharma) who contribute synthesis, formulation, and commercialization capabilities while AniMusCure contributes mechanism research and AI-led lead optimization, with future revenue expected from licensing royalties and overseas technology export. Clinical operations are outsourced via a CRO agreement with Novotech, and Phase 2 trials are conducted at Seoul National University Hospital and three other Korean sites. A complementary consumer revenue stream was added in December 2024 with the launch of M-Qure Plus, a liquid magnesium health functional food, representing a non-Rx, channel-based sales motion alongside the prescription pipeline.

Animascure firmographics

Firmographics
Name
Animascure
Legal name
AnimusCure Inc. (애니머스큐어 주식회사)
Website
https://animuscure.com
Company type
Private
Founded year
2020
Operating status
Operating
Short description
AniMusCure is a South Korean clinical-stage biotech developing first-in-class therapeutics for sarcopenia, DMD, ALS, and other muscle diseases using proprietary AI-powered MyoCheck and hiPSC organoid platforms, monetizing through pharma licensing and co-development with Dongwha, REYON, and Il-Yang.
Ownership category
akta.pro rank

Animascure industry classification

Industry
Product category
Muscle Disease Therapeutics R&D
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAKAIAD
Neuromuscular Medicine (ALS, Myasthenia, Neuropathy)
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAGAD
Organoids & Organ-on-Chip (regenerative models)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHSADAFAC
Weight Gain & Muscle-Building Nutrition

Keywords

  • Muscle disease therapeutics
  • Sarcopenia drug development
  • AI drug discovery platform
  • HiPSC organoid technology
  • Orphan drug designation

Where Animascure is headquartered

Location

Headquarters

HQ city
Cheongcheon
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

Animascure business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Development and Licensing: Pre-revenue biotech company focused on developing novel therapeutics for muscle diseases including sarcopenia, DMD, ALS, and cardiovascular conditions. Revenue expected through licensing deals with global pharmaceutical companies, co-development agreements, and eventual product commercialization.
  2. Health Functional Food Sales: Launched M-Qure Plus liquid magnesium product in December 2024 for muscle health, representing a consumer health product revenue stream.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Animascure product offering

Product offering

Core offering

Animascure is a clinical-stage biotechnology company developing first-in-class small-molecule drug candidates that simultaneously increase muscle mass, enhance muscle strength, and improve muscle function for sarcopenia, DMD, ALS, cancer cachexia, metabolic syndrome, and cardiovascular indications. Its drug discovery is powered by the proprietary AI-driven MyoCheck® platform and hiPSC-based NeuroMuscular and Heart Organoid modeling platforms, with future revenue expected from out-licensing and co-development deals with global pharmaceutical partners and a current consumer revenue stream from the M-Qure Plus liquid magnesium health supplement.

Product overview

AnimusCure is a muscle-focused R&D biotechnology company developing a portfolio of drug candidates for muscle-related diseases. The core product pipeline includes AMC6156 for sarcopenia and ALS, AMC8012 for DMD, AMC9005 for metabolic syndrome, AMC8011 for obesity combination therapy, and AMC6133 for cancer cachexia. The company operates two technology platforms: the AI-powered MyoCheck® Platform for drug discovery enabling rapid candidate identification within 3-6 months, and the Organoid Platform using hiPSC-based neuromuscular and heart organoids for disease modeling and drug evaluation. Additionally, the company launched M-Qure Plus, a liquid magnesium health supplement for muscle health in January 2025.

Differentiator

Problem solved

Functional benefit

Brands

  • M-Qure Plus: Health functional food - liquid magnesium supplement for muscle health launched in December 2024

Products and services

  • AMC6156 Lead small-molecule drug candidate targeting age-related sarcopenia with a first-in-class triple-action mechanism that simultaneously increases muscle mass, enhances muscle strength, and improves muscle function. Currently in Phase 2 clinical trials in Korea for sarcopenia and has received FDA Orphan Drug Designation for ALS.
  • AMC8012 Drug candidate for Duchenne Muscular Dystrophy (DMD), a rare congenital muscle disease, with FDA Orphan Drug Designation. Targets progressive muscle degeneration in pediatric and rare-disease populations.
  • AMC9005 Drug candidate for metabolic syndrome including obesity treatment, with FDA Orphan Drug Designation approved. Developed through the proprietary core target gene-based therapeutic approach.
  • AMC8011 Obesity combination therapy drug candidate designed to address muscle-loss side effects associated with GLP-1 weight-loss drugs; third-party efficacy study completed in combination with GLP-1.
  • AMC6133 Drug candidate targeting cancer cachexia, the muscle-wasting syndrome associated with malignancy and oncology treatments.
  • M-Qure Plus Liquid magnesium dietary supplement marketed as a health functional food for muscle health, providing a consumer-facing revenue stream alongside the pharmaceutical pipeline.

Quantifiable outcome

  • Candidate compound identification within 3-6 months using MyoCheck platform
  • +1 more outcomes

Companies that use Animascure

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Animascure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Animascure partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core and minor.

  • REYON Pharmaceutical (이연제약)coreStrategic or Co-development Partner · 7 January 2025Joint research agreement signed for age-related sarcopenia treatment development. Both companies utilizing their strengths to conduct joint R&D with goals of overseas technology export and domestic approval acquisition.
  • Il-Yang PharmaceuticalcoreStrategic or Co-development Partner · 7 January 2025Memorandum of understanding signed for joint R&D on age-related sarcopenia therapeutics. Partnership aims for overseas technology export and domestic regulatory approval.
  • NovotechcoreImplementation/ SI/ Consulting Partner · 3 July 2023CRO agreement for Phase 2a clinical trial of AMC6156 sarcopenia treatment. Novotech serves as clinical research organization for trial conduct and management.
  • Dongwha PharmaceuticalcoreStrategic or Co-development Partner · 31 August 2022Joint research agreement for sarcopenia treatment development. Dongwha Pharmaceutical synthesizes and derives sarcopenia treatment candidates using low-molecule compound-based new drug development capabilities. AniMusCure conducts efficacy evaluation and mechanism research. Joint patent applications filed with Dongwha receiving commercialization rights.
  • Samik Pharma (삼익제약)minorStrategic or Co-development Partner · 13 June 2022Academic-industry collaboration with Sookmyung Pharmacy School and AniMusCure for muscle disease therapeutic development. Samik Pharma invests research funding and handles drug characterization, formulation optimization, and IND filing. AniMusCure conducts mechanism of action research and AI-based lead optimization.
  • Sookmyung Women's UniversitycoreStrategic or Co-development PartnerAcademic research partner hosting AniMusCure's headquarters and 2nd Research Institute at the university. CEO Bae Gyu-Un serves as professor at the College of Pharmacy and directs the Muscle Physiome Research Center (MRC).
  • Sungkyunkwan UniversitycoreStrategic or Co-development PartnerAcademic research partner hosting AniMusCure's 1st Research Institute at the School of Medicine. CTO Jongsoon Kang serves as professor at the School of Medicine and leads ARPA-H project for sarcopenia therapeutics.
  • Zuellig PharmaminorOthersListed as partner in company materials, nature of partnership not detailed in available sources.
  • PiramalminorOthersListed as partner in company materials, nature of partnership not detailed in available sources.
  • AsymchemminorOthersListed as partner in company materials, nature of partnership not detailed in available sources.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Animascure competitors and assessment

Company assessment

Direct peers

  • Sarepta Therapeutics: Commercial-stage leader in Duchenne Muscular Dystrophy with multiple approved RNA-based therapies (Elevidys, Exondys 51, Vyondys 53). Directly comparable for the DMD program (AMC8012) given same indication and rare-disease commercial dynamics.
  • Keros Therapeutics: Clinical-stage biotech developing therapeutics targeting TGF-beta superfamily for blood disorders and muscle/bone diseases. Comparable given shared muscle-biology focus and similar clinical-stage profile.
  • Avidity Biosciences: Clinical-stage biotech developing Antibody Oligonucleotide Conjugates for rare muscle diseases including DMD, FSHD, and DM1. Directly comparable given shared DMD focus and rare muscle-disease strategy.
  • BioAge Labs: Clinical-stage biotech developing therapeutics that target the molecular mechanisms of aging, with a lead program for sarcopenia. Most directly comparable to AnimusCure given shared sarcopenia focus, AI-driven discovery, and similar stage of development.
  • Cytokinetics: Late-stage biotech specializing in muscle biology and cardiac contractility, with approved cardiac myosin inhibitor and pipeline in HCM and muscle function. Directly comparable for muscle-targeted therapeutics development and clinical execution.
  • Scholar Rock: Clinical-stage biotech developing monoclonal antibodies targeting latent myostatin and TGF-beta superfamily for muscle disorders including SMA and DMD. Closely comparable given muscle-disease focus and similar therapeutic modality ambition.

Broad incumbents

  • Regeneron Pharmaceuticals: Large-cap biotech with muscle-related programs (e.g., garetosmab for fibrodysplasia ossificans progressiva) and broad rare-disease portfolio. Comparable as a potential global partner/acquirer with the capital to in-license sarcopenia assets.
  • Biogen: Large biotech with established ALS franchise (Spinraza, Relyvrio withdrawal) and active neuromuscular pipeline. Comparable as a likely acquirer/licensor for AnimusCure's ALS program and as a broad neuromuscular incumbent.
  • Insmed: Commercial rare-disease biotech with approved ARIKAYCE and pipeline in pulmonary and rare diseases. Comparable given rare-disease commercialization playbook and orphan-drug expertise applicable to AnimusCure's DMD/ALS programs.

Emerging players

  • Lexeo Therapeutics: Clinical-stage gene therapy company with focus on genetic cardiomyopathies and rare diseases. Comparable as a platform-oriented biotech tackling muscle/cardiovascular rare diseases at similar stage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Animascure social profiles

Digital presence

Animascure compliance and trust

Trust signal

Compliance2 records

Animascure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Animascure leadership team

Management profile

Number of profiles

Profiles2 records

Animascure funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Animascure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Animascure

What does Animascure do?

Animascure is a clinical-stage biotechnology company developing first-in-class small-molecule drug candidates that simultaneously increase muscle mass, enhance muscle strength, and improve muscle function for sarcopenia, DMD, ALS, cancer cachexia, metabolic syndrome, and cardiovascular indications. Its drug discovery is powered by the proprietary AI-driven MyoCheck® platform and hiPSC-based NeuroMuscular and Heart Organoid modeling platforms, with future revenue expected from out-licensing and co-development deals with global pharmaceutical partners and a current consumer revenue stream from the M-Qure Plus liquid magnesium health supplement.

Is Animascure a public or private company?

Animascure is a private company. It is classified as venture growth investor backed and is currently operating.

When was Animascure founded?

Animascure was founded in 2020.

Where is Animascure based?

Animascure is headquartered in Cheongcheon, South Korea, in the Asia region.

How does Animascure make money?

Two revenue lines are on record. Drug Development and Licensing is the primary driver. The others are health Functional Food Sales.

Who are Animascure's main competitors?

Direct peers on record are Sarepta Therapeutics, Keros Therapeutics, Avidity Biosciences, BioAge Labs, Cytokinetics and Scholar Rock. Broad incumbents are Regeneron Pharmaceuticals, Biogen and Insmed. Lexeo Therapeutics is listed as an emerging player.

Does Animascure have an API?

No public API is recorded for Animascure.

What industry is Animascure in?

Animascure's product category is Muscle Disease Therapeutics R&D. Its primary akta.pro industry code is HLAKAIAD, Neuromuscular Medicine (ALS, Myasthenia, Neuropathy), with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales